Kariyama K, Kumada T, et al, Group OBOTRPEFHRS, Group H. Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. Cancers (Basel). 2019 Feb 10; 11(2). pii: E203
Itokawa N, Kumada T, et al. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatol Res. 2019Feb; 49(2):125-135
Toyoda H, Kumada T, et al. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Liver Int. 2019 Mar; 39(3):448-454
Tada T, Kumada T, et al. Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. AJR Am J Roentgenol. 2019 Feb; 212(2):332-341
Atsukawa M, Kumada T, et al. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J Gastroenterol Hepatol. 2019 Feb; 34(2):364-369
Hiraoka A, Kumada T, et al.Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. J Gastroenterol Hepatol. 2019 Feb; 34(2):436-441
Ito T, Kumada T, et al. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. J Gastroenterol Hepatol. 2019 Jan; 34(1): 207-214
Nakashima M, Kumada T, et al. Influence of Renal Dysfunction on Dose Reduction and Virological Efficacy of Regimens Combining Ribavirin and All-Oral Direct Acting Antivirals in Patients with Chronic Hepatitis C Virus Infection. Hepatol Res. 2019 Jan 10
Hiraoka A, Kumada T, et al; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res. 2019 Jan; 49(1):111-117
Hiraoka A, Kumada T, et al; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2018 Dec 21
Tada T, Kumada T, et al. Impact of ALBI grade on survival in patients with HCC who received sorafenib: an analysis using time-dependent ROC. J Gastroenterol Hepatol. 2018 Dec 14
Maekawa T, Kumada T, et al. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem Biophys Res Commun. 2018 Dec 2; 506(4):962-969
Chan AWH, Kumada T, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018 Dec; 69(6):1284-1293
Hayashi K, Kumada T, et al. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. J Viral Hepat. 2018 Dec; 25(12):1446-1451
Toyoda H, Kumada T, et al. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. Liver Int. 2018 Dec; 38(12):2260-2268
Atsukawa M, Kumada T, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res. 2018 Nov 28
Tada T, Kumada T, et al. Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. J Gastroenterol. 2018 Nov; 53(11):1196-1205
Yasuda S, Kumada T, et al. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication. J Gastroenterol Hepatol. 2018 Nov; 33(11):1904-1911
Matsuura K, Kumada T, et al. Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. Open Forum Infect Dis. 2018 Oct 22;5(11):ofy268
Toyoda H, Kumada T, et al. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther. 2018 Sep; 48(6):664-670
Shinkai N, Kumada T, et al. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol. 2018 Jul; 53(7):883-889
Toyoda H, Kumada T, et al. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Gastroenterol Hepatol. 2018 Jun; 33(6):1264-1270
Kudo M, Kumada T, et al; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jun; 3(6):424-432
Toyoda H, Kumada T, e al. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2018 May 8
Kobayashi N, Kumada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol. 2018 May; 30(5):546-551
Tada T, Kumada T, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1012-1022
Tada T, Kumada T, et al. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018 Apr; 33(4):918-925
Ishigami M, Kumada T, et al. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol. 2018 Apr; 90(4):736-744
Kaibori M, Kumada T, et al; Liver Cancer Study Group of Japan. Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort. Ann Surg. 2018 Mar 30
Rho JH, Kumada T, et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018 Mar; 67(3):473-484
Okubo T, Kumada T, et al. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int. 2018 Mar; 12(2):133-142
Toyoda H, Kumada T, et al. Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR. J Hepatol. 2018 Mar; 68(3):606-607
Takayasu K, Kumada T, et al; Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int. 2018 Mar; 38(3):484-493
Hiraoka A, Kumada T, et al; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. Hepatol Res. 2018 Feb; 48(3):E61-E67
Tada T, Kumada T, et al. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers. 2018 May - Jun; 23(4):328-334
Suda G, Kumada T, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018 Jan; 53(1):119-128
Toyoda H, Kumada T, et al. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci. 2017 Dec; 108(12):2438-2444
Tada T, Kumada T, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017 Dec; 32(12):1982-1988
Ishigami M, Kumada T, et al. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data. J Gastroenterol Hepatol. 2017 Nov; 32(11):1879-1886
Hiraoka A, Kumada T, et al. ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function. Liver Cancer. 2017 Nov; 6(4):377-379
Hiraoka A, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017Nov; 6(4):325-336
Fukami Y, Kumada T, et al. Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases. Int J Surg. 2017 Oct; 46:79-84
Toyoda H, Kumada T, et al; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017 Oct; 52(10):1112-1121
Toyoda H, Kumada T, et al. Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. Ther Apher Dial. 2017 Oct; 21(5):465-472
Tada T, Kumada T, et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017 Sep 26; 1(9):899-910
Kaibori M, Kumada T, et al; Liver Cancer Study Group of Japan. Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. Ann Surg. 2017 Sep 15
Tada T, Kumada T, et al. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C. Hepatol Res. 2017 Sep; 47(10):1021-1031
Kokudo T, Kumada T, et al; Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology. 2017 Aug; 66(2):510-517
Dengler M, Kumada T, et al. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget. 2017Jul 11; 8(28):46234-46248
Tada T, Kumada T, et al. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. Cancer Sci. 2017 Jul; 108(7):1414-1420
Tada T, Kumada T, et al. Reply to: "HBV markers for HCC prediction: Three heads are better than two?" J Hepatol. 2017 Jul; 67(1):204-205
Toyoda H, Kumada T, et al. Hepatitis B Core-Related Antigen: A Possible Indicator for the Termination of Prophylactic Nucleos(t)ide Analogue Therapy in Patients After Immunosuppressive Therapy. Am J Gastroenterol. 2017 Jun; 112(6):969-970
Matsushima-Nishiwaki R, Kumada T, et al. Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway. Biochim Biophys Acta Mol Basis Dis.2017 Jun; 1863(6):1629-1639
Honda T, Kumada T, et al. Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B. Clin Microbiol Infect. 2017 Jun; 23(6):407.e1-407.e7
Toyoda H, Kumada T, et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat. 2017 Jun; 24(6):472-476
Hiraoka A, Kumada T, et al; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer. 2017 Jun; 6(3):204-215
Ishigami M, Kumada T, et al. Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction. Clin Gastroenterol Hepatol. 2017 May; 15(5):787-788
Matsuura K, Kumada T, et al; Japanese Genome-Wide Association Study Group for Viral Hepatitis. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. Gastroenterology. 2017 May; 152(6):1383-1394
Toyoda H, Kumada T, et al. Discrepant imaging findings of portal vein thrombosis with dynamic computed tomography and computed tomography during arterial portography in hepatocellular carcinoma: possible cause leading to inappropriate treatment selection. Clin J Gastroenterol. 2017 Apr; 10(2):163-167
Hiraoka A, Kumada T, et al; Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. Mol Clin Oncol. 2017 Apr; 6(4):455-461
Tada T, Kumada T,et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017 Mar; 32(3):687-694
Toyoda H, Kumada T, et al. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017 Mar; 66(3):521-527
Tada T, Kumada T, et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017 Mar; 32(3):687-694
Toyoda H, Kumada T, et al. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017 Mar; 66(3):521-527
Waked I, Kumada T, et al. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017 Feb 14; 116(4):448-454
Johnson P, Kumada T, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017 Feb 14; 116(4):441-447
Tada T, Kumada T, et al. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol. 2017 Feb; 32(2):451-458
Inoue T, Kumada T, et al. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. PLoS One. 2017 Jan 24; 12(1):e0170667
Toyoda H, Kumada T, et al. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV. Antivir Ther. 2017; 22(3):185-193
Hiraoka A, Kumada T, et al; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Dig Dis.2017; 35(6):602-610
Kobayashi N, Kumada T, et al. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients. Dig Dis. 2017; 35(6):521-530
Aoki T, Kumada T, et al. Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. J Gastroenterol. 2017 Jan; 52(1):104-112
Tada T, Kumada T, et al. Utility of combined gray-scale and perflubutane contrast-enhanced ultrasound for diagnosing early hepatocellular carcinomas: Comparison of well differentiated and distinctly nodular types. Hepatol Res. 2016 Nov; 46(12):1214-1225
Toyoda H, Kumada T, et al. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology.2016 Nov; 64(5):1818-1819
Hayashi K, Kumada T, et al. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy. J Gastroenterol. 2016 Nov; 51(11):1081-1089
Okanoue T, Kumada T, et al. Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatol Res. 2016 Sep; 46(10):992-1001
Takada K, Kumada T, et al. Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system. Eur J Radiol. 2016 Aug; 85(8):1400-6
Toyoda H, Kumada T, at al. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. Hepatol Res. 2016 Jul; 46(8):734-42
Terashita K, Kumada T,et al. ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. J Clin Pathol. 2016 Jul; 69(7):593-9
Toyoda H, Kumada T, et al. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Jul; 51(7):741-7
Chan AW, Kumada T, et al. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. J Gastroenterol Hepatol. 2016 Jul; 31(7):1300-6
Tada T, Kumada T, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol. 2016 Jul; 65(1):48-56
Berhane S, Kumada T,et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol. 2016 Jun; 14(6):875-886
Tada T, Kumada T, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016 Jun; 36(6):817-26
Maekawa T, Kumada T, et al. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis. World J Gastroenterol. 2016 May 7;2 2(17):4403-10
Hiraoka A, Kumada T, et al, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis? : A multicenter study. Hepatol Res. 2016 May; 46(6):521-8
Hiraoka A, Kumada T, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016 May; 31(5):1031-6
Matsushima-Nishiwaki R, Kumada T, et al. Phosphorylated Heat Shock Protein 20 (HSPB6) Regulates Transforming Growth Factor-α-Induced Migration and Invasion of Hepatocellular Carcinoma Cells. PLoS One. 2016 Apr 5; 11(4):e0151907
Tada T, Kumada T,et al. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol. 2016 Apr; 51(4):380-9
Toyoda H, Kumada T, et al: a novel biomarker with diagnostic and therapeutic implications in liver diseases'. Liver Int. 2016 Apr; 36(4):613
Toyoda H, Kumada T, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer. 2016 Mar 29; 114(7):744-50
Ueda M, Kumada T, et al. Specific increase in serum core-fucosylated haptoglobin in patientswith chronic pancreatitis. Pancreatology. 2016 Mar-Apr; 16(2):238-43
Toyoda H, Kumada T, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 2016 Feb; 36(2):293-301
Kanamori A, Kumada T, et al. Long- and short-term outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis. Endosc Int Open. 2016 Jan; 4(1):E83-90
Hiraoka A, Kumada T, et al. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. Oncology. 2016; 91(3):153-61
Takahashi H, Kumada T,et al. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res. 2015 Dec; 45(12):1220-7
Takada K, Kumada T, et al. Accurate and rapid identification of feeding arteries with multidetector-row angiography-assisted computed tomography for transarterial chemoembolization for hepatocellular carcinoma. J Gastroenterol. 2015 Dec; 50(12):1190-6
Ueshima K, Kumada T, et al. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer. 2015 Dec; 4(4):263-73
Tada T, Kumada T, et al. Utility of Contrast-enhanced Ultrasonography with Perflubutane for Determining Histologic Grade in Hepatocellular Carcinoma. Ultrasound Med Biol. 2015 Dec; 41(12):3070-8
Tada T, Kumada T, et al. Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices. Hepatol Res. 2015 Oct; 45(10):E122-9
Ito T, Kumada T, et al. Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. J Viral Hepat. 2015 Oct; 22(10):777-83
Tada T, Kumada T, et al. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis. J Gastroenterol Hepatol. 2015 Sep; 30(9):1412-9
Tachi Y, Kumada T, et al. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One. 2015 Jul 27; 10(7):e0133515
Ito T, Kumada T, et al. FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol. 2015 Jul; 141(7):1311-9
Tada T, Kumada T,et al. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy. J Gastroenterol.2015 Jul; 50(7):795-804
Toyoda H, Kumada T, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015 Jul; 30(7):1183-9
Abe H, Kumada T, et al. Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype. Hepatol Res. 2015 Apr; 45(4):387-96
Toyoda H, Kumada T, et al. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery. 2015 Apr; 157(4):699-707
Toyoda H, Kumada T, et al. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015 Mar; 4(2):126-36
Johnson PJ, Kumada T, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015 Feb 20; 33(6):550-8
Honda T, Kumada T, et al. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C. J Gastroenterol Hepatol. 2015 Feb; 30(2):321-8
Nagasawa T, Kumada T, et al. Heat shock protein 20 (HSPB6) regulates TNF-α-induced intracellular signaling pathway in human hepatocellular carcinoma cells. Arch Biochem Biophys. 2015 Jan 1; 565:1-8
Toyoda H, Kumada T, et al. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int. 2015 Jan; 9(1):84-92
Tada T, Kumada T, et al. Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. J Gastroenterol. 2015 Jan; 50(1):85-94
Hayashi K, Kumada T, et al. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. J Gastroenterol Hepatol. 2015 Jan; 30(1):178-83
Furukawa K, Kumada T,et al.Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Pancreas. 2015 Jan; 44(1):93-8
Toyoda H, Kumada T, et al. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 2014 Dec; 142(12):2624-8
Shimada N, Kumada T, et al. A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Hepatol Res.2014 Dec; 44(14):E386-96
Shimada N, Kumada T, et al. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol. 2014 Nov; 49(11):1485-94
Murakami Y, Kumada T, et al. Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014 Sep 12; 9(9):e106314
Tada T, Kumada T, et al. Utility of contrast-enhanced ultrasound with perflubutane for diagnosing the macroscopic type of small nodular hepatocellular carcinomas. Eur Radiol. 2014 Sep; 24(9):2157-66
Nagasawa T, Kumada T, et al. Heat shock protein 20 (HSPB6) regulates apoptosis in human hepatocellular carcinoma cells: Direct association with Bax. Oncol Rep. 2014 Sep; 32(3):1291-5
Toyoda H, Kumada T, et al. Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results? Hepatology. 2014 Aug; 60(2):762-3
Toyoda H, Kumada T, et al. Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med. 2014 Jun; 3(3):643-51
Fox R, Kumada T, et al. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014 Apr 15; 110(8):2090-8
Tada T, Kumada T, et al. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis. Hepatol Res. 2014 Mar; 44(3):288-95
Kumada T,et al. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014 Mar; 49(3):555-63
Katano Y, Kumada T, et al. Biochemical staging of thechronic hepatic lesions of Wilson disease. Nagoya J Med Sci. 2014Feb; 76(1-2):139-48.
Toyoda H, Kumada T, et al. Transnasal Endoscope Locked in a Bent Position Causing Difficult Withdrawal. ACG Case Rep J. 2014 Jan 10; 1(2):79-81.
Abe H, Kumada T, et al. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014; 2014:549709.
Toyoda H, Kumada T, et al. Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy. Intervirology. 2014; 57(5): 289-96.
Toyoda H, Kumada T, et al. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients. J Clin Gastroenterol. 2014 Jan; 48(1):73-9.